J&A to extend Period or Performance for procurement of Inmazeb
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- JOFOC-REG-1
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSO100201700016C Federal contract award
- Awardee
- Regeneron Pharmaceuticals Inc.
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- Tarrytown, New York, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response has awarded a modification to contract HHSO100201700016C to Regeneron Pharmaceuticals Inc. on a sole-source basis for procurement of Inmazeb (Ebola virus therapeutic) for the Strategic National Stockpile, with a modification value of $297,715,850.15, bringing total contract value to $990,772,776.82.
The justification cites FAR 6.302-1, only one responsible source. Inmazeb is the only FDA-approved Ebola therapeutic meeting government requirements and Strategic National Stockpile storage standards. Market research confirmed that Inmazeb and Ebanga are the only FDA-approved Ebola therapeutics as of January 2026; Ebanga remains unavailable for procurement until 2028. The product must demonstrate efficacy against Ebola virus in animal models, possess an acceptable safety profile, be compatible with SNS storage and packaging, and meet current Good Manufacturing Practice standards.
The modification supports manufacture and delivery of up to 26,500 doses through 2031 and addresses a government requirement for 753,000 therapeutic treatment courses. The pricing structure is hybrid cost-plus fixed fee and firm-fixed price. Regeneron is located at 777 Old Saw Mill River Road, Tarrytown, NY. The original contract was awarded in 2017 following competitive RFP procedures and remains actively performed. All required approvals, including legal review, competition advocate review, OSDBU review, and HCA approval, have been obtained.
Notice text
J&A to extend Period or Performance for procurement of Inmazeb.
Awarded contract HHSO100201700016C to unknown vendor for unknown amount on 2026-09-25.
Files
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity